Naji Gehchan: Hello, leaders of the world. Welcome to “Spread Love in Organizations”, a podcast for purpose-driven healthcare leaders, striving to make life better around the world by leading their teams with genuine care, servant leadership, and love.
I am Naji, your host for this special episode in partnership with ESCP Business School and its specialized Masters in Pharma and Biotech Management. I am joined today by Clarissa Gorin a pharmacist and ESCP alum. Following her initial professional experience focusing on the blockchain industry and the fight against counterfeit medicines in developing countries, Clarissa joined Ad Scientiam in 2020 as Head of Medical Affairs. Ad Scientiam, a MedTech company originating from the Paris Brain Institute, specializes in developing digital biomarkers that enable the monitoring and prediction of the progression of certain neurodegenerative pathologies and rare diseases. These innovative markers are derived from proprietary algorithms for measuring precise analysis movements, vocal activity, or image processing derived from smartphone sensors and AI technologies.
Clarissa, It’s great to have you with me today!
Clarissa Gorin: Yeah. Well, thank you for the invitation and for the great introduction and, uh, the opportunity to, to share my professional experience and, uh, insights in the medtech, uh, sector, which, um, I hope will be useful to, to others.
Naji Gehchan: I’m sure it will. So before we go into this passion you have since, uh, early on about innovative tech and now AI that became a big subject. Can you first tell us more about your personal story, uh, why becoming a pharmacist, now being a leader in this edge of tech innovation and healthcare?
Clarissa Gorin: Yeah. Well, sure.
Thanks for the question. So I think, well, I come from a family of, uh, doctors, so like the health, uh, sector was always a subject when I started to, to look for different, um, well, specialization and, and, um, well, um, uh, formation. Uh, so it all started quite classically, uh, with this, uh, pharmacy, uh, sector, uh, from which I chose, uh, the industry sector.
Um, I wanted first, uh, to build a career in the pharmaceutical marketing, uh, but much more related to the drug, uh, industries. And, um, with my first Pharmacy diploma in hand, I joined this, uh, ESCP, a master of science, um, specialized in pharmaceutical and biotech, um, management. Um, for me, it was very interesting because the, the pharmacy sector is very, offers a wide range of, um, professional, um, path, uh, such as hospital, uh, city based pharmacy and industry.
Um, so for me, who wasn’t very sure about, uh, what type of, um, well, Pathway I wanted to embrace. It was interesting to have such a different options. Um, but very quickly, uh, doing the, the ESCP master of science, I was, um, quickly offered the first, uh, opportunity, uh, professional opportunity, um, which. Can we say diverted me from this classic path of marketing and in pharma?
As I joined the entrepreneurial adventure, uh, doing the master with some former classmates from the faculty of pharmacy who were launching this, uh, by a blockchain, uh, technology project that you were talking about, um, with the ambitious aim to fight, uh, fake drugs in sub Saharan Africa. Um, so yeah, well, I believe that, uh, it was very interesting.
It was much more related to, you know, uh, public health, uh, consideration and despite my knowledge in the, well, drug system, drug, uh, distribution process, I was, you know, Immediately confronted with a new challenges, um, both in terms of, you know, understanding a new technology, the blockchain, uh, which was very famous in that hand and also a major, um, cultural differences, um, in a, in a market that was very different from France.
Um, we, we were able to travel a lot, uh, to Hebrew coast. Um, so yeah, it was a very. Interesting first experience and a great opportunity for me, uh, going from a more classic path of, uh, industry and pharma to, uh, open my eyes to new, uh, horizon. And in particular, uh, to grow my, my passion for the application of new technologies to the healthcare field.
Naji Gehchan: I want to go a little bit there because it’s a, it’s a great, uh, experience on how you’re framing, uh, try to, uh, you went from the, what you say, the classical path. into more tech. You also discovered other challenges that we do not face in countries because you’re, we’re talking now you’re in Paris and France.
So, um, where, where you had, uh, your, your studies, um, and also entrepreneurial. So there’s, different levels of cultural differences that you had from work to also the patients who were serving. So I’d love to go there and understand now after the facts, when you look back, what is the key learning, uh, or the key leadership lessons that you had through the experiences you’ve been having.
Clarissa Gorin: Sure. So yeah, for me, it was very, um, instructive, uh, first experience because as you said, uh, we were coming from our well, well developed, uh, countries idea, um, project proposition. And, uh, once arriving in, uh, Africa, um, Hebrew coast, it was really a challenge to understand the cultural differences also, uh, regarding the adoption of new technologies.
Uh, you know, we were. Coming there was a great idea to fight this fake medicine problems, which is very important in such countries. But we had also this very fine tuning technology called blockchain, where we wanted to capitalize, to capitalize in. And it was sometimes very difficult for us to, well, to educate also the local population of the potential of, uh, such a fake medicines and also, uh, the usage of such a new technologies.
Um, even, you know, like, uh, using a smartphones, uh, on a daily basis, but not something that was so usual at the time, uh, in Africa in comparison to, um, well, um, Europe and, uh, specifically, uh, Africa. Um, so for me, uh, it was. Very, uh, important, uh, to understand and to have adaptability process, uh, in mind, uh, to make sure that we adapt the technology to the real needs of the fields.
And it was, I mean, for me, it’s one of the most important, um, capacity of, uh, leaders is to have a great adaptability mind process to support, uh, agile. Team culture and also personal cultures of work, um, to be able, you know, to quickly, um, react if there is some, uh, dynamics, for example, here, a new challenge in new countries, uh, with different cultures, uh, to be able to adapt, um, such technology in the, in this case.
But also, um, it enables great leaders to encourage. And exploit new opportunities and to take on new challenges. So I think it was maybe for me, the greatest lesson learned on this first experience, that we need to adapt our thoughts and beliefs to the actual needs of the market. And especially for new technologies that come from another situation and other markets to be able to adapt it to local specificities.
Naji Gehchan: So do you look now at new technologies in a different way about how they would actually impact patients across the globe?
Clarissa Gorin: Yes, sure. Um, so I believe that my different, uh, now look on a new technology and in particular in this, uh, medical sector, uh, is that sometimes, uh, we do not need to have the most sophisticated, uh, technology to be able to tackle some, uh, specific needs, you know, sometimes when we discuss with, uh, doctors, nurses, um, in, uh, hospital centers, uh, Um, they describe us their needs and their daily problems.
And sometimes we just look back and say, you know, we don’t need a very fancy technologies to be able to answer to that need. So it’s really a challenge for us working in the tech where we want to make sure that our technologies are adopt, adopted, um, by every populations. But sometimes, I mean, a. For us, it’s, uh, it’s important also to know, uh, where we do not need actually, um, new technology to answer this needs.
Um, it’s very different, I believe, from, um, other industry, um, where sometimes it’s the more important is actually the, the technical concept of the technology, but I’m pretty sure and from now on to have been able to discuss with lots of different stakeholders in the medical sectors, it’s much more related to if there is a specific challenges and what is the fit for people’s technologies that could answer to this needs to be able to achieve a full adoption by the different users.
Naji Gehchan: Thanks. So that’s, that’s a great points you’re bringing. And really it reminds me like there’s. We’re a lot of work actually in the healthcare sector, as you know, about low tech that can actually improve and impact patients. So there’s always this idea of certainly high tech has done tremendous work, and we’re going to talk about this and where you’re excited.
But not forgetting that some. Some places low tech can really bring a huge impact for people. Uh, and we, we should continue to consider it.
Clarissa Gorin: Yeah, totally. Uh, low tech, but also, uh, making sure that, um, all, uh, accessibility aspects are taking, um, in consideration when developing and conceiving, uh, this technology products.
Uh, we’ve been working, uh, in AdSensia means very different, uh, age courses of patients, uh, meaning children. uh, elderly patients. And, um, every time we ask ourselves what is the best technology to be able to achieve accessibility, uh, so, you know, like, uh, capacity of, uh, using the tool. Uh, but also, uh, there is some accessibility aspects related to, uh, disabling aspects of such a chronic disease, uh, hearing loss, for example, and other aspects.
And, um, it’s true that sometimes, um, new technologies are the answers, but sometimes they are not. And so, I mean, being humble about, uh, what those type of high tech, uh, products can, uh, can perform and achieve in the health tech sector, um, is very important, um, for me, uh, so on.
Naji Gehchan: Yeah. And how you’re framing it, uh, would correct me if I’m wrong.
I’m feeling like we should always think about. What do we want to achieve and the technology, whether it’s like super high tech or it’s not, is actually just a mean.
Clarissa Gorin: Sure. And it’s just a mean, and also it could be different, uh, with different means, you know, like being able to really identify which is the specific medical challenges or.
Unmet needs that you want to tackle, um, is very important. And for one specific medical challenges, you could think about different, um, tech solutions to, to answer to it. Um, and for us, sometimes, uh, um, we, when we start a new project, um, we can identify that sometimes our projects are not the best solution to answer as a specific medical challenge.
And it’s. It’s totally, uh, okay to, to, to stop, uh, the project and to answer that we do not have, um, the best project to answer this and to be able to, yeah, once again, being humble about, um, what your, your project can do and what is not the best, uh, to do is very important.
Naji Gehchan: And it starts, as you just said, with the unmet medical need.
It really starts with patients. What are we trying to solve to make their life better?
Clarissa Gorin: Totally patients, um, but also doctors, uh, sometimes, um, we can see that, you know, in particular in France, uh, we, uh, where we have a public health sector, um, that sometimes, um, isn’t. Is in difficulty. Uh, sometimes we can see some very specific national, um, um, errors or like challenges, uh, to be tackled by new technologies.
Uh, I believe that there is a lot to do in hospital centers, expert centers, uh, to make sure that, um, the whole, uh, care pathway is more efficient. And also, you’re totally right. Much more related to, um, well. Direct benefits for patients and for their daily life, but both are very important to understand, um, either if it’s a specific, um, medical for doctor use or a patient use, because it will be very different in your, um, development process and, um, well, concept phase, um, to be sure to have the best fit for people’s, um, project.
Naji Gehchan: Awesome. So we just said, and you said that you don’t have like, there’s not only one solution, there is several and it depends, but I’m going to still ask you this question, since you’ve been in this field and you’re looking into the future, which one of these solutions do you think Or a couple of these emerging techs are you most excited about for the next decade that you really think they are going to change our health?
Clarissa Gorin: Yeah, well, of course, I will talk about, uh, well, digital biomarkers because, you know, I’m working on it and I believe there is a lot of to do. Um, but also I would say that, um, Well, AI and VR can also have a lot to do. For example, uh, I’ve seen a lot of projects, um, coming from virtual, uh, reality systems, uh, that could have a strong impact in the field of, for example, digital therapeutics, uh, where we can see that such tools can be used, um, to be Really like intervention based driven by software programs to, uh, help prevent, uh, manage or treat some medical disorders and disease.
Uh, for example, like VR can be used to, uh, treat, um, chronic pain or, for example, to, uh, Hades, um, in, uh, rehabilitation programs by, uh, incorporating sensors and, um, software technology to provide a real time feedback and guidance to, to patients, uh, directly at home. So it’s really something, uh, that can be very useful in, for example, neuromuscular disease, uh, other orthopedic, uh, diseases.
Regarding artificial intelligence in particular, um, we’ve been, uh, understanding and hearing a lot regarding how, uh, AI will, uh, replace, uh, human doctors in the near future. Um, I really don’t think it would be the case. Uh, I much more think that it will become critical tools, um, to help augment medical practice and, um, much more important to reduce the burden for healthcare providers.
So for example, we can think about diagnostic tools that helps doctors to improve real time decision making for clinicians. For example, by analyzing a lot and a lot of data at the same time, so the healthcare provider, uh, Could not be able to do it from, for example, a patient’s medical records or scientific articles or medical guidelines, um, for example, to give, uh, some treatment recommendation or to identify some drug interactions, uh, much more easily, uh, and with a tons of data analyzed at the same times.
Regarding, uh, digital biomarkers, um, for me, I believe that, uh, such tools as you introduced, uh, that are really new measures of, uh, physiological or comportmental, um, aspects of, uh, patients and that are, um, generated directly by patients by the means of, uh, digital devices. Uh, they have the power to really, um, well, understand some mechanisms that are not well understood so far, for example, to monitor or predict, uh, some diseases and specifically neurological diseases.
Uh, where we know that, uh, usual biomarkers such as, uh, imaging biology are not fully, uh, sufficient to understand the clinical evolution and response to treatment of individual patients. So, it’s a really a major, uh, research challenges for clinicians and, um, well, for the scientific community at a whole.
And, um, for me, it was very, uh, important. Um, to try to see how those digital biomarkers could be useful in such a pathology. Uh, so yeah, well, I think it’s a three examples. I know that there is tons of more, um, but I see here some very, uh, specific and practical, um, aspects and, uh, objectives because we know there is also lots and tons of technologies that are still in research and development, but.
That have not, um, well, indication and usage are ready for the next years.
Naji Gehchan: Thank you so much, uh, Clarissa for for this. Can can you give us a couple of one or two use cases, for example, for digital biomarkers, which is one of the specialties here. And I’m interested to learning more on specific use cases that have had an impact on research or on patients.
Clarissa Gorin: Yeah, sure. Uh, well, maybe some first, uh, example that we, that we have, um, I could say that, uh, in multiple sclerosis, that is a neurological disease, autoimmune disease, um, where we know that patients are evolving, uh, during the years and progressively, um, going into a late progressive phase, uh, where they tend to act Cumulate some disabling aspects of their disease, um, and which is the first cause of, um, disability in young patients after traumatic cases.
So really, uh, major. public health impact, um, for such disease and where, uh, as so far, it’s very difficult, uh, for clinicians, so mainly a neurologist, uh, to understand, uh, why some patients are progressing more rapidly than others. And we know that it’s a very specific challenge, uh, to know and to detect Earlier, uh, when a patient will be progressively, um, going into this progressive phase of the disease, uh, where it’s very important to, for example, adapt the treatment, uh, to slow down the disease and, uh, and, and stop the, the progression of the disease, uh, um, inherently.
And so here, uh, we know that So typical biomarkers are not, um, sufficient to detect and predict the true moments, uh, where such patients will be, uh, while transforming into their disease phase. And that’s where, uh, one hypothesis is that, um, digital biomarkers by enabling, uh, much more frequently measures of the functional impact of the disease of the patients, for example, regarding the walking capacities.
Cognitive impact, uh, vision related disabilities are upper limb and dexterity impacts, uh, would be able to gather enough data, enough specific and sensible, uh, markers, uh, to be able to detect it, um, earlier. So that’s one hypothesis, uh, that we have as so far, um, it’s something that is already used by neurologists, um, just to, uh, well monitor.
For, um, their patients and for example, see if there is a deterioration, uh, when we, they put in place some novel treatments to assess, uh, the individual treatment response of patients and for example, switch treatment earlier if we see that there is a negative impact. So maybe that’s one example, uh, much more related to patient care, um, but also research because of course it’s very important for industry players, um, to making sure that they have some specific markers of response to treatment to be able to treat earlier the good patients at the right, at the right time.
Um, so yeah, that could be, uh, maybe some, uh, first, uh, example. And maybe the second example that I could have, um, a recent example that we saw, uh, much more related to psychiatry, uh, where we know also that it’s very, uh, difficult to understand the different, the different biomechanical pathway of, uh, in a psychiatry and much more in acute phases of psychiatry, uh, dimension.
And, um, another example that, uh, that we developed, uh, and is, uh, currently in the clinical validation phase is to being able to identify novel digital biomarkers of, uh, treatment response in a antidepressant, um, populations. The challenge that we wanted to tackle is that, uh, so far when a patient, um, a major depressive patient, um, is, um, uh, being prescribed some antidepressant, uh, medications, uh, we need to wait a long time to be a, being able to really see if, uh, this treatment is, um, efficient on the patient or not.
So the hypothesis is that we developed some vocal biomarkers of the voice of the patient, uh, which we know, uh, are correlated to their depressive state or not. And with the combination of lots of other biomarkers, um, it could, uh, be, we could be able to detect very early if the patient is, uh, uh, answering to, to his treatment, uh, or not.
Those
Naji Gehchan: are great examples. I want to ask you how you’re thinking about, uh, sensors. Voice recognition. How does this get incorporated in patients lives? Because we’re like surrounded by sensors. Right. And what I have like one watch here, another one here, do I have to input the data? And I’m not, I’m not going to go into, unless you want to like all the GDPR data, privacy field of science.
Right. Uh, but really more from a user. If I’m thinking about a user, me as a patient. And the amount of sensors I would have and how I interact with them, how I make sure they’re giving you the information. How are you guys thinking about this? Is it like a new technology, like physical sensors or technologies you’re bringing?
Are you trying to incorporate with whatever the big tech companies have? How do you think about that?
Clarissa Gorin: Well, I believe it’s very depending, uh, on the, well, usage and indication, uh, that you want to achieve, um, for us. Um, it’s very important that, uh, the technological tool is incorporating in the real life of the user.
So, uh, we want to. Capitalize of some tools that the patient already have in his own hand. So that’s why we mainly work on the smartphone of the patient, making possible to transform the smartphone into a really a medical recording system that the patient doesn’t have to, you know, to, to equip and to buy another external sensor that is sometimes difficult to put in, uh, in his own daily life.
Well, if it’s, for example, for a clinical study or for a research based, uh, program, where we know that is, uh, you know, during a certain amount of time, uh, but it’s, uh, only during a few weeks or a few months, we can totally imagine to have like, uh, a very specific, uh, external sensor, very, um, sensitive, very, uh, very, uh, hard tech, uh, product.
But if, uh, we believe into a real life usage as, uh, we are working with in, in Adsenciam, we try to work, uh, with the most, um, you know, known, uh, products of patients at no cost. For patients. It’s very important for us also to achieve equity. Um, and, uh, well, large usage, adoption in the, in the general population.
Uh, so that’s why we, we capitalize on the different sensors that are already embedded in the smartphone. Um, it’s totally possible to work also with, uh, some external sensors that the patient would. Already have, uh, it’s always just a question of interoperability, uh, that, uh, well, Lots of, uh, technical providers can, uh, can put in place.
Um, but if you’re all Just talking about a clinical study, clinical research usage, it’s very difficult different because you, you know, you don’t have all this user experience requirements to put in place as there is no long term adoption and usage questions to to answer to. tool. So, I mean, it really depends on the type of projects, but for real life usage, we totally recommend, and that’s what patients are telling us, uh, to use the, the most easy tools that they already, almost all of them have in their pockets, which is, which is the smartphone or smartwatch or any other, um, known product for, for patients and easy to use.
Naji Gehchan: So Clarissa, I want to give you now a word and I would love your reaction to it. The first one is leadership.
Clarissa Gorin: Um, well, I would say to answer that, I would say, um, leadership is about organizing and training, uh, the collective, uh, to, uh, maybe extract its, uh, best. quintessence, if we can say. Um, it’s always to being, making all the different people, uh, working together to achieve, uh, same and common, uh, objective.
But also, uh, the second word that I would, uh, that I would keep is authenticity. Um, it’s what I try to apply, uh, to, to the best every day, uh, is to, um, well, Staying true to yourself, being transparent about your strengths and areas for development, um, especially in the med tech sector, uh, where there is a lot of uncertainty, um, related to projects or businesses, uh, scenario.
Um, so for me, it’s really not enough to have a great competence expertise, uh, to being a great leader. It’s much more related to. Um, people trusting you and trusting your integrity. Um, and also feel a direct and personal connection with you. This is why I place a great emphasis on the importance of, um, you know, sharing passion, personal, personal information, um, with the team.
Um, because, uh, I believe, yeah, like authenticity and confidence, um, is very important because otherwise, um, people will be reluctant to, to take risk and to, uh, to, to work alongside, uh, with you. So, yeah, I would say like, uh, this, uh, It’s three aspects, if I would say, um, organizing and training the collective together, but also, uh, bringing more intensity, uh, authenticity, sorry, and, um, and also, uh, sharing some, uh, uh, always, uh, personal information and, uh, and gaining trust of the people that are around, uh, around you.
Naji Gehchan: The second word is diversity. ,
Clarissa Gorin: um, diversity, I’m sorry if it’s not a, a single word . It’s, that’s fine. That’s fine. Sometimes it’s a, it’s a bit, uh, longer. Um, but diversity, uh, specifically in the, in the MedTech, uh, sector, I would say that, uh. Very important, and also for leader working in this sector, is to making sure that the different projects that we develop are alongside this different diversity that patients can have.
So yeah, diversity and inclusion, I would say in terms of both words. Um, we know that for a long time, uh, this high tech products, uh, were mainly developed, um, for well profitable populations and, uh, well, not, uh, used by all of the different. diverse population, uh, that were targeted. Um, and I know, uh, that, uh, the medtech sector can really help improve, uh, such a diversity and inclusion in the healthcare system.
For example, um, capitalize of such a techno capitalize on such technologies to Improve the diversity in clinical trials could be very important. Um, for example, you know, like adding some new device that could make able some, um, uh, participants to to join the clinical studies that are living abroad that are living in, uh, or the types of population that were not Principally targeted in, uh, in clinical research, uh, can be, uh, important.
Naji Gehchan: I love this and I love this great example. I’m working heavily on diversity in clinical trials with, with my team. So yeah, we can, we can have another session specifically on that. Yeah,
Clarissa Gorin: totally. Well, I really believe that, uh, well new, new texts and, uh, for example, as such a, well, smartphone based or like connected device, um, to be included as a, You know, like digital endpoints in clinical studies could have a great impact in diversity and inclusion of different populations that we usually don’t see in clinical trials of, of a drug, of new drugs, clinical trials.
Naji Gehchan: The third one is blockchain.
Clarissa Gorin: Blockchain. So, well, I would say, uh, a lot of, uh, a lot of noise, uh, a lot of, um, uh, how to say, um, Lots of, uh, I don’t remember how to say, uh, uh, a lot of hope. Yeah. Sorry. A lot of hope that was, uh, that was done in, uh, in the health healthcare sector, uh, regarding, uh, the blockchain.
Um, I remember that, uh, when we started, uh, on this first project, uh, on the fake medicine, uh, um, project, uh, we were hoping that, uh, such tool could could, you know, like help, uh, tracking the different, uh, path of the supply chain of, uh, drug systems. We believed, um, because it was also from the financial, um, industry that it could help, uh, well, tackle some, uh, specific breach of information related to drug distribution, um, process.
Um, but so far, uh, not a lot of, uh, well, scenarios and applicable, um, solutions. Um, so yeah, I would say a lot of hope, uh, at that time. Um, but still some, uh, um, some scenarios of specific projects, uh, to, to be, to be developed.
Naji Gehchan: The last word is spread love and organizations.
Clarissa Gorin: Well, spread love in organization, um, I mean, for me, much, much, uh, related to, uh, what we discussed so far to, um, well, promote, uh, well, authenticity and also, uh, promote, um, uh, trust around people, um, by.
giving them the opportunity also to discuss, to talk, to have their own point of view in our process. That’s really something that we try to put in place, um, at, uh, at Atsensium. Um, you know, it’s, it’s very, um, It’s very, uh, scaling dynamic in this health tech, uh, startup environment. Um, when we know that there is, uh, some more junior profiles that are coming, some tech profiles that are not, uh, always, um, Very well known about the healthcare sector.
And for me, a spread love in an organization would say like giving the opportunity to each to give their own point of view, uh, as part of their process, as part of our process, methodology, uh, just making sure, um, that even if it’s, you know, there is not this lots of, uh, yeah, she, uh, in between the different people in the organization, but making sure that, uh, All the, the different voice of people I heard and, uh, also, uh, putting trust into this, uh, different people.
Naji Gehchan: Any final word of wisdom, uh, Carissa, for healthcare leaders around the world?
Clarissa Gorin: Um, when I would say that, uh, for me, and I, I’m not a great example of it, uh, leadership is not, uh, innate gift or like, uh, superman, uh, abilities, uh, that people are born with. Um, I believe it’s really, you know, a journey of self discovery.
Self development, um, much more related to willingness to embrace, uh, learning, learning new things. Um, it involves usually like stepping beyond, uh, comfort zones. Um, maybe immersing in, uh, unfamiliar territory as I did at the very beginning of my professional path, uh, you know, like coming from the classical, uh, pharma industry sector, uh, believing, uh, I would be, uh, uh, joining a marketing or commercial path to a new technology, blockchain, digital biomarker, artificial intelligence, uh, which for me was really new I didn’t have, and it.
It could only be your life. I’m telling you that I always had this, uh, you know, this, uh, mindset for tech and, uh, and nerd profile, which is not the case at all. Uh, so yeah, immersing in, uh, unfamiliar territory and, uh, maybe navigating, um, challenges to, well, Ultimately inspire and try to guide others. Um, I would say that are, well, yeah, the most important aspects of, um, such leaders.
And in particular in the, the med tech sector, uh, where we know, uh, once again, that there is a lot of uncertainty, uh, it’s really a constantly involving, evolving and dynamic, um, environment. Um, so very important to, uh, well, Step aside and try a new thing to, to try to, um, to collect new also, uh, inputs and insights from others to, to, to try to guide them at the end.
Naji Gehchan: What a great way to, uh, finish our chat. I love how you framed it. Leadership is a journey of self-development. That’s a great charge for all of us as leaders. Thank you so much, uh, for joining me today and, uh, for this great conversation.
Clarissa Gorin: Well, thanks to you, uh, thanks for the opportunity also to, um, once again to to share my, uh.
Well, young experience, but, uh, I hope, uh, interesting for others. Um, there is a lot of opportunity in the med tech sector, a lot to do. Uh, there is still new things that we, we, we identify and that we, we believe could be done in the next future. So thanks again for the opportunity and for the really nice chat with you.
Naji Gehchan: Thank you all for listening to SpreadLove in Organizations podcast. Drop us a review on your preferred podcast platform.
Thank you all for listening to Spreadlove in Organizations podcast! More episodes in partnership with ESCP Business School are available on spreadloveio.com or on your preferred podcast app. Follow “spreadlove in organizations” wherever you listen to podcasts and spread the word around you to inspire others and amplify this movement our World so desperately needs.
Follow us on LinkedIn and connect with us on spreadloveio.com. We’re eager to hear your thoughts and feedback. Most importantly, spread love in your organizations and spread the word around you to inspire others and amplify this movement, our world so desperately needs.